Purpose: Transanal total mesorectal excision (TaTME) was developed to overcome surgical difficulties experienced in distal pelvic dissection. Concerns have been raised about potential worse postoperative functional outcomes after TaTME. Also, the oncological safety was questioned. This study aimed to describe the functional, surgical, oncological outcomes and quality of life (QoL) after TaTME.

Methods: All consecutive TaTME cases for rectal cancer without disseminated disease between December 2016 and April 2019 were included. The Wexner incontinence score, low anterior resection syndrome (LARS) score, fecal incontinence-related QoL, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-core questionnaire and 29-item module (EORTC QLQ-C30/CR29) were collected. Kaplan-Meier analysis was used to calculate local recurrence-free survival.

Results: Thirty patients were eligible for analysis of which 23 received questionnaires. Response rate was 74%. After a median follow-up of respectively 20.0 and 23.0 months for functional and oncological outcomes, the median (interquartile range) of Wexner incontinence and LARS scores were 9.0 (7.0–12.0) and 33.1 (25.0–39.0). Major LARS was present in 73.3%. Fecal incontinence, general and colorectal-specific QoL subdomains that are associated with poor bowel function scored in line with previously reported data. The 2-year actuarial cumulative local recurrence rate was 3.7% (95% confidence interval, 2.4%–5.0%).

Conclusion: TaTME may lead to significant functional impairments. Patients should receive preoperative counseling on this topic and be fully aware of the potential consequences of their treatment. Oncological data were in line with other short- to moderate-term data and did not show alarming results.

Keywords: Colorectal surgery; Patient reported outcome measures; Functional status; Quality of life

INTRODUCTION

Total mesorectal excision (TME) is the most effective surgical treat-
Outcomes of interest

Surgical and oncology-related outcomes

Collected data included stoma construction rate, type of anastomosis, number of operating teams, conversion rate, reoperation within 30 days, length of hospital stays, LR rate, and incidence of metastasis during follow-up. Next to this, postoperative complications such as anastomotic leakage (AL) rates were collected. An AL was defined as associated clinical symptoms and increased inflammatory markers with contrast extravasation on computed tomography scan and/or a defect visible during endoscopy [20]. The Dutch guidelines for routine follow-up were followed.

Patient-reported outcome measures

Patients with a stoma received the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-core questionnaire and 29-item module (EORTC QLQ-C30/CR29), while patients with bowel continuity also received the low anterior resection syndrome (LARS) score, Wexner incontinence score, and Fecal Incontinence Quality of Life (FIQL).

LARS score: This score is validated for scoring bowel dysfunction after low anterior resection for colorectal cancer. Reference data are documented [21]. It covers the 5 most bothersome issues in terms of prevalence and impact of QoL, namely incontinence for flatus and liquid stool, frequency, clustering, and urgency. Scores range from 0 to 42, with subdivisions in 3 categories; no (0–20), minor (21–29), and major LARS (30–42).

Wexner incontinence scale: This questionnaire assesses the severity, type and frequency of fecal incontinence, and its impact on daily life. Scores range from 0 (continent) to 20 (highest severity of incontinence), with categories of asymptomatic (0), minor (1–4), moderate (5–8), and severe (>8) incontinence. It has an important association with the FIQL score [22].

Fecal Incontinence Quality of Life: The FIQL score is a condition-specific questionnaire on QoL and consists of 4 multi-item subscales; lifestyle, coping/behavior, depression/self-perception, and embarrassment. Scores range from 1 to 4 where 1 represents a low QoL and 4 represents a high QoL [23]. The FIQL questionnaire does not categorize scores into clinical groups.

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire: The modules CR29 and C30 version were used to measure colorectal cancer-specific and general QoL [24, 25]. Scores range from 0 to 100; a higher score represents a higher (“better”) level of functioning or a higher (“worse”) level of symptoms. No categorization of scores is used, but EORTC QLQ-C30 reference population scores are available.

Statistical analysis

All categorical data were presented as percentages, where a mean with standard deviation (SD) or median with interquartile range (IQR) was presented for continuous data, depending on distribution of data. Where appropriate, 95% confidence intervals (CI) were provided. For the EORTC QLQ linear transformation of raw
Table 1. Patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>TaTME total group (n = 30)</th>
<th>TaTME questionnaire completer (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>65.5 ± 9.0</td>
<td>67.2 ± 7.0</td>
</tr>
<tr>
<td>Males</td>
<td>24 (80.0)</td>
<td>12 (70.6)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25.6 (23.5–27.8)</td>
<td>25.6 (23.3–28.9)</td>
</tr>
<tr>
<td>ASA PS classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>6 (20.0)</td>
<td>3 (17.6)</td>
</tr>
<tr>
<td>II</td>
<td>21 (70.0)</td>
<td>12 (70.6)</td>
</tr>
<tr>
<td>III</td>
<td>3 (10.0)</td>
<td>2 (11.8)</td>
</tr>
<tr>
<td><strong>Follow-up oncological results (mo)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up of questionnaires (mo)</td>
<td>23.0 (17.0–29.3)</td>
<td>-</td>
</tr>
<tr>
<td>Stoma status at time of questionnaires</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never had a stoma</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Temporary stoma, already closed</td>
<td>19</td>
<td>11</td>
</tr>
<tr>
<td>Stoma still present</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td><strong>Tumor characteristic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor height from anal verge (cm)</td>
<td>4.0 (2.0)</td>
<td>4.0 (2.8)</td>
</tr>
<tr>
<td>Height of the anastomosis from anal verge (cm)</td>
<td>24 (80.0)</td>
<td>13 (76.5)</td>
</tr>
<tr>
<td>0–5.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.1–10.0</td>
<td>6 (20.0)</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>Clinical TNM stageab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>T2</td>
<td>11 (36.7)</td>
<td>7 (41.2)</td>
</tr>
<tr>
<td>T3</td>
<td>17 (56.7)</td>
<td>8 (47.1)</td>
</tr>
<tr>
<td>T4</td>
<td>2 (6.7)</td>
<td>2 (11.8)</td>
</tr>
<tr>
<td>N0</td>
<td>18 (60.0)</td>
<td>11 (64.7)</td>
</tr>
<tr>
<td>N1</td>
<td>7 (23.3)</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>N2</td>
<td>4 (13.3)</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>N3</td>
<td>1 (3.3)</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>M0</td>
<td>24 (80.0)</td>
<td>13 (76.5)</td>
</tr>
<tr>
<td>Mx</td>
<td>6 (20.0)</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>ypTNM stage, no metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT0</td>
<td>3 (10.3)</td>
<td>2 (11.8)</td>
</tr>
<tr>
<td>pT1</td>
<td>5 (17.2)</td>
<td>2 (11.8)</td>
</tr>
<tr>
<td>pT2</td>
<td>11 (37.9)</td>
<td>6 (35.3)</td>
</tr>
<tr>
<td>pT3</td>
<td>10 (34.5)</td>
<td>7 (41.2)</td>
</tr>
<tr>
<td>N0</td>
<td>22 (75.9)</td>
<td>11 (64.7)</td>
</tr>
<tr>
<td>N1</td>
<td>5 (17.2)</td>
<td>5 (29.4)</td>
</tr>
<tr>
<td>N2</td>
<td>2 (6.9)</td>
<td>1 (5.9)</td>
</tr>
</tbody>
</table>

*Continued to the next page*

Table 1. Continued

<table>
<thead>
<tr>
<th>Variable</th>
<th>TaTME total group (n = 30)</th>
<th>TaTME questionnaire completer (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of pathologically assessed EMVI</td>
<td>2 (6.7)</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>Presence of pathologically assessed lymph-invasion</td>
<td>2 (6.7)</td>
<td>2 (11.8)</td>
</tr>
<tr>
<td>Additional therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neoadjuvant</td>
<td>14 (46.7)</td>
<td>9 (52.9)</td>
</tr>
<tr>
<td>Short course radiotherapy, 5 × 5 Gy</td>
<td>7 (23.3)</td>
<td>5 (29.4)</td>
</tr>
<tr>
<td>Chemoradiationc</td>
<td>7 (23.3)</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>Adjuvant chemotherapy</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation, number (%), median (interquartile range), or number only.

TaTME, transanal total mesorectal excision; ASA, American Society of Anesthesiologists; PS, physical status; yp, postneoadjuvant pathologic stage; EMVI, extramural vascular invasion.
aTumor height assessed by magnetic resonance imaging.
bClinical T-stadia that were reported as T1–2 were classified as T2.
cChemoradiation consisted of 25 × 2 Gy radiotherapy and capecitabine of 825 mg/m² twice a day.

scores was used for analysis, following the EORTC scoring manual [24]. Kaplan-Meier analysis was used to calculate LR-free cumulative survival at 24-months from the date of surgery. In this analysis, patients were censored when lost to follow up. No censoring for other oncological reasons (such as metastasis) took place. IBM SPSS Statistics ver. 25.0 (IBM Corp., Armonk, NY, USA) was used.

RESULTS

Between December 2016 and April 2019, 30 patients underwent TaTME for rectal cancer in Máxima Medical Centre, Veldhoven, the Netherlands and were eligible for evaluation. A total of 23 patients were eligible for questionnaire inclusion. The remaining 7 were excluded due to dementia (n = 1), previously reported wish not to participate in studies (n = 3) or death (n = 3). Four patients returned blank questionnaires, 2 did not respond and 17 completed them all, leading to a response rate of 74%. Table 1 provides all patient characteristics for the whole group and questionnaires completers separately. In the text below, the whole group (n = 30) is described. Most patients were male (80.0%) with a median body mass index of 25.6 kg/m² (IQR, 23.5–27.8 kg/m²). Most of the tumors were located in the first 5 cm from the anal verge (80.0%) and almost half of the patients underwent neoadjuvant treatment (46.7%). The median follow-up time for questionnaire completion was 20.0 months (IQR, 13.0–23.0 months). Three patients died during follow-up of which 1 was 2 days after surgery due to sepsis, 1 due to cerebral hemorrhage 2 months after surgery, and 1 cause remained unknown (progressive dementia and living in a nursing home). Bowel continuity at the time of study conduction
was 76.7% (23 of 30) for the whole group and 88.2% (15 of 17) for questionnaire completers. Three patients received their stoma after their initial TaTME surgery (2 due to postoperative complications, 1 due to fecal incontinence).

**Fecal incontinence, bowel dysfunction, and its impact on quality of life**

Table 2 provides functional outcome scores. The median Wexner incontinence score was 9.0 (IQR, 7.0–12.0). All 15 non-stoma patients were symptomatic since respectively 6.7%, 33.3%, and 60.0% of patients had mild, moderate, and severe incontinence. Analyzing individual patient records showed that 1 out of 3 patients was referred to a pelvic floor rehabilitation center. Median FIQL scores were respectively 3.7, 3.1, 3.3, and 3.7 for the domains of lifestyle, coping/behavior, depression/self-perception, and embarrassment. The median LARS score was 33.1 (IQR, 25.0–39.0) and 73.3% reported major LARS. One patient chose for the construction of a stoma due to complaints of fecal incontinence, while 5 others preferred transanal irrigation to improve their QoL (which it subjectively did according to notes in the patient files). Patients who used transanal irrigation reported that they scored their functional outcomes according to the situation prior to the start of irrigation.

Table 3 provides QoL data. Mean global health status was 82.8 ± 12.7. Values are presented as mean ± standard deviation.

**Table 2. Overview of Wexner incontinence, LARS, and FIQL scores**

<table>
<thead>
<tr>
<th>Scale</th>
<th>TaTME group (n=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wexner incontinence score</td>
<td></td>
</tr>
<tr>
<td>Total score</td>
<td>9.0 (7.0–12.0)</td>
</tr>
<tr>
<td>Degree of incontinence</td>
<td></td>
</tr>
<tr>
<td>Not symptomatic (&lt;1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Mild (1–4)</td>
<td>1 (6.7)</td>
</tr>
<tr>
<td>Moderate (5–8)</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Severe (&gt;8)</td>
<td>9 (60.0)</td>
</tr>
<tr>
<td>LARS score</td>
<td></td>
</tr>
<tr>
<td>Total score</td>
<td>33.1 (25.0–39.0)</td>
</tr>
<tr>
<td>LARS category</td>
<td></td>
</tr>
<tr>
<td>No LARS</td>
<td>1 (6.7)</td>
</tr>
<tr>
<td>Minor LARS</td>
<td>3 (20.0)</td>
</tr>
<tr>
<td>Major LARS</td>
<td>11 (73.3)</td>
</tr>
<tr>
<td>FIQL score</td>
<td></td>
</tr>
<tr>
<td>Lifestyle</td>
<td>3.7 (3.4–4.0)</td>
</tr>
<tr>
<td>Coping/behavior</td>
<td>3.1 (2.1–3.4)</td>
</tr>
<tr>
<td>Depression/self-perception</td>
<td>3.3 (3.2–3.8)</td>
</tr>
<tr>
<td>Embarrassment</td>
<td>3.7 (3.0–4.0)</td>
</tr>
</tbody>
</table>

Values are presented as median (interquartile range) or number (%). LARS, low anterior resection syndrome; FIQL, Fecal Incontinence Quality of Life; TaTME, transanal total mesorectal excision.

**Table 3. Overview of EORTC QLQ C30 and CR29**

<table>
<thead>
<tr>
<th>Category</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>QLQ C30 (n=17)</td>
<td></td>
</tr>
<tr>
<td>Global health status</td>
<td>82.8 ± 12.7</td>
</tr>
<tr>
<td>Physical functioning</td>
<td>92.2 ± 10.1</td>
</tr>
<tr>
<td>Role functioning</td>
<td>86.3 ± 17.9</td>
</tr>
<tr>
<td>Emotional functioning</td>
<td>88.7 ± 15.6</td>
</tr>
<tr>
<td>Cognitive functioning</td>
<td>94.1 ± 10.1</td>
</tr>
<tr>
<td>Social functioning</td>
<td>88.2 ± 14.1</td>
</tr>
<tr>
<td>Fatigue</td>
<td>15.0 ± 13.6</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>1.0 ± 4.0</td>
</tr>
<tr>
<td>Pain</td>
<td>9.8 ± 16.7</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>0</td>
</tr>
<tr>
<td>Insomnia</td>
<td>19.6 ± 23.7</td>
</tr>
<tr>
<td>Appetite loss</td>
<td>1.9 ± 8.1</td>
</tr>
<tr>
<td>Constipation</td>
<td>15.7 ± 33.6</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>9.8 ± 15.7</td>
</tr>
<tr>
<td>Financial difficulties</td>
<td>3.9 ± 11.1</td>
</tr>
<tr>
<td>QLQ CR29 (n=17)</td>
<td></td>
</tr>
<tr>
<td>Body image</td>
<td>10.5 ± 12.1</td>
</tr>
<tr>
<td>Anxiety</td>
<td>17.6 ± 17.1</td>
</tr>
<tr>
<td>Weight loss</td>
<td>19.6 ± 29.0</td>
</tr>
<tr>
<td>Urinary frequency</td>
<td>27.5 ± 26.9</td>
</tr>
<tr>
<td>Blood and mucus in stool</td>
<td>13.7 ± 23.7</td>
</tr>
<tr>
<td>Dysuria</td>
<td>2.0 ± 8.1</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>15.7 ± 31.4</td>
</tr>
<tr>
<td>Buttock pain</td>
<td>11.8 ± 20.2</td>
</tr>
<tr>
<td>Bloating</td>
<td>19.6 ± 31.3</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>35.3 ± 83.7</td>
</tr>
<tr>
<td>Hair loss</td>
<td>0</td>
</tr>
<tr>
<td>Taste</td>
<td>3.9 ± 16.2</td>
</tr>
<tr>
<td>Flatulence</td>
<td>41.7 ± 35.5</td>
</tr>
<tr>
<td>Fecal incontinence</td>
<td>8.3 ± 14.9</td>
</tr>
<tr>
<td>Sore skin around anus</td>
<td>10.4 ± 20.1</td>
</tr>
<tr>
<td>Stool frequency</td>
<td>20.8 ± 17.7</td>
</tr>
<tr>
<td>Embarrassment</td>
<td>12.5 ± 16.7</td>
</tr>
<tr>
<td>Sexual interest, men (n=12)</td>
<td>36.1 ± 22.3</td>
</tr>
<tr>
<td>Impotence, men</td>
<td>47.2 ± 43.7</td>
</tr>
<tr>
<td>Sexual interest, women (n=5)</td>
<td>40.0 ± 43.5</td>
</tr>
<tr>
<td>Dyspareunia, women (n=4)</td>
<td>16.7 ± 33.3</td>
</tr>
</tbody>
</table>

Values are presented as mean ± standard deviation. EORTC, European Organization for Research and Treatment of Cancer; C30, core questionnaire; CR29, 29-item module.

*No stoma-related quality of life is presented in this table since only 2 patients reported on this.*
Table 4. Surgical and oncological outcomes of all included 30 patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical outcome</td>
<td></td>
</tr>
<tr>
<td>Construction of a temporary stoma at index surgery</td>
<td>No, primary anastomosis 7 (23.3)</td>
</tr>
<tr>
<td></td>
<td>Yes, deviating or permanent stoma 23 (76.7)</td>
</tr>
<tr>
<td>Stoma closed at the present time</td>
<td>20 (66.7)</td>
</tr>
<tr>
<td>Time to stoma closure (mo)</td>
<td>3.0 (2.0–4.0)</td>
</tr>
<tr>
<td>Complications and morbidity</td>
<td></td>
</tr>
<tr>
<td>Perioperative complications</td>
<td>0</td>
</tr>
<tr>
<td>Postoperative morbidity/mortality</td>
<td>7 (23.3)</td>
</tr>
<tr>
<td>Abscess (localized at rectum remnant)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Ileus</td>
<td>2 (6.7)</td>
</tr>
<tr>
<td>Anastomotic leakage</td>
<td>3 (10.0)</td>
</tr>
<tr>
<td>Number that had a protective stoma</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Death due to sepsis</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Type of anastomosis:</td>
<td></td>
</tr>
<tr>
<td>End to end</td>
<td>23 (76.7)</td>
</tr>
<tr>
<td>Coloanal</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>Permanent colostomy (intersphincteric resection)</td>
<td>2 (6.7)</td>
</tr>
<tr>
<td>Number of 2-team procedures</td>
<td>18 (60.0)</td>
</tr>
<tr>
<td>Conversion rate</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Time of surgery (min)</td>
<td>298 (239–356)</td>
</tr>
<tr>
<td>Reoperation within 30 days</td>
<td>6 (20.0)</td>
</tr>
<tr>
<td>Hospitalization (day)</td>
<td>7.5 (4.0–11.5)</td>
</tr>
<tr>
<td>Oncological outcome</td>
<td></td>
</tr>
<tr>
<td>Local recurrence</td>
<td>2* (6.7)</td>
</tr>
<tr>
<td>If yes: time till recurrences (mo)</td>
<td>6*, 9, 10, and 24</td>
</tr>
<tr>
<td>Metastasis during follow-up</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>If yes: time till metastasis (mo)</td>
<td>6*, 9, 10, and 24</td>
</tr>
</tbody>
</table>

Values are presented as number (%) or median (interquartile range).
\*This resembles 1 patient that presented itself with both a local recurrence as with pulmonary, lymphatic, and peritoneal metastasis at 6-month follow-up.

(SD, 12.7) and all other functioning scales scored higher than 88.0 points. The colorectal-specific submodule showed scores of respectively 41.7, 20.8, and 12.5 for the symptom scales flatulence, stool frequency, and embarrassment. FIQL scored 8.3 points.

Surgical and oncological outcomes in the first set of transanal total mesorectal excision patients

Table 4 provides all surgical and oncological outcomes. In the first 30 patients that were treated in this hospital, no conversions were needed. The median time of surgery was 310 minutes and no nameable intraoperative complications occurred. In 23.3%, no protective stoma was constructed next to an anastomosis at index surgery. The majority (70.0%) received a diverting ileostomy next to the construction of an anastomosis at index surgery, while the remaining 67.7% received another stoma type, such as a colostomy. In 2 patients, a definitive colostomy was constructed. Serious postoperative complications such as abscesses, ileus, and AL occurred in respectively 3.3%, 6.7%, and 10.0% of the cases, while 1 patient died due to postoperative sepsis with multiorgan failure due to an ischemic afferent colon based on poor microcirculation, not related to AL. Six patients underwent reoperations within 30 days (range, 2–7 days) after index surgery. Reasons were AL (n = 2), suspicion of AL (n = 1), second look due to sepsis with multiorgan failure (n = 1), and nonfunctioning diverting stomata (n = 2).

Regarding oncologic results, after a median follow-up of 23.0 months (IQR, 17.0–29.3 months), an LR was found in 2 patients. Patient 1, initially postneoadjuvant pathologic stage (yp) T3N1M0 and MRF– (treated with neoadjuvant 5 × 5 Gy radiotherapy), presented itself with both a unifocal LR precoccygeal and extensive systemic disease at 6 months and received palliative chemotherapy. Patient 2, initially ypT3N1M0 and MRF+, showed a unifocal presacral LR at 27 months of follow-up and started with induction chemotherapy followed by chemoradiotherapy and surgery. No angioinvasion, extramural vascular invasion, or R1 resection at first surgery were reported for both. No multifocal recurrence pattern was seen. The 2-year actuarial cumulative LR rate, censored for patients lost to follow up, was 3.7% (95% CI, 2.4%–5.0%) (Fig. 1).

DISCUSSION

This institutional cohort study investigated the functional outcome and QoL of the first 30 patients that underwent TaTME for rectal cancer in a teaching hospital in the Netherlands and reported both surgical and oncologic outcomes. Functional complaints, in-
cluding fecal incontinence, are common after TaTME but are compatible with good QoL if patients accept and support their treatment options. After a median follow-up of 23 months, oncological outcomes did not show any alarming results.

Since more patients outline their cancer diagnosis, QoL and functional outcomes become more important. This study found a median LARS score of 33.1 and a prevalence of 73.3% major LARS. Previous studies reported major LARS percentages ranging from 21% to 84% [6, 14, 26-30] and median LARS scores that were lower (range, 10–36) than reported in the current cohort [6, 14, 26-30]. However, study populations did not covarient, especially since higher located tumors [6, 27], shorter follow-up times [14, 28], and lower [27] or higher (this study reported 84.0% major LARS) [28] neoadjuvant treatment rates were reported compared with the present study. A study with similar patient characteristics showed similar results [30].

All patients showed some form of incontinence since no patient scored a Wexner incontinence score of zero. The median Wexner incontinence score was 9.0 which is in line with previously reported data [15, 28, 31, 32]. These previous studies were comparable to our cohort regarding patient characteristics such as age, sex, and tumor height, although the follow-up time in 2 of them was shorter (3–6 months) [28, 32]. This suggests that no large improvements over time can be expected. In the study presented by Rubinkiewicz et al. [28], neoadjuvant treatment was more frequently used (up to 96%), explaining a higher median Wexner incontinence score (11; range, 8–12). Regarding FIQH subdomains, scores did not differ from long-term data elsewhere [33] and didn’t show clinically significant differences compared to a Dutch reference population [34]. Analyzing colorectal specific QoL showed that most domains that are associated with LARS were in line with previously reported data, namely flatulence (41.7; elsewhere, range, 22.2–51.3), stool frequency (20.8; elsewhere, 19.8–36.4), and sore skin around the anus (10.4; elsewhere, 2.5–33.3). Surprisingly, the symptom scale domains fecal incontinence and embarrassment scored lower than previously reported, respectively 8.3 (elsewhere, 20.4–37.0) and 12.5 (elsewhere, 23.3–68.9) [6, 14, 15, 27, 35, 36]. Important to notice is that one patient choose to get a permanent purse-string placement [19].

When discussing surgical outcomes and operation details, it is important to acknowledge that the surgeons were in their learning phase [38]. Although the AL and abscess rate (combined 13.3%) was similar as described in the learning curve evaluation study of Koedam et al. [38], the overall major postoperative morbidity (20% complications that required re-intervention) was lower. Since the percentage of overall major postoperative morbidity can be used as a sensitive learning curve marker, it shows that our surgeons follow a steeper learning curve than the original pioneers in the field [38]. Other factors, such as the rate of construction of a primary anastomosis or time of hospitalization, showed no differences with previously reported studies, although the time of surgery was longer [38]. We emphasize the importance of a structured training pathway and proctoring program when adopting a new surgical technique, especially since TaTME can be challenging with regard to technical set-up, correct plane dissection, and purse-string placement [19].

The LR-free survival after TaTME was assessed as well. Within a median follow-up time of 23.0 months, 2 patients developed an LR. This represents a 2-year actuarial cumulative LR rate of 3.6% (95% CI, 2.4%–5.0%). It was the LR rates from previous studies, in the example of the Norwegians, that were alarming in the introduction phase of TaTME [7]. They reported short-term LR rates of 8% to 10% with an unconventional multifocal pattern and early occurrence, which is why the Norwegians stopped performing TaTME. However, recent multicenter data on 2- and 3-year LR rate (3.3% and 4.5%, respectively; n = 767) from Roodbeen et al. [10] showed comparable results as with laparoscopic and open TME [39, 40]. Although our results are derived from a small study population, no alarming results were found.

This study is limited by a small study population with relatively short to moderate follow-up time regarding oncological outcomes, although follow-up time is enough to report on postoperative function and QoL. Due to this small study population, some of the reported standard deviations, especially in the EORTC QoL list, are high. Also, this study reports the outcomes of the first 30 patients that underwent this challenging technique. Learning curve studies showed that postoperative outcomes improved after the first 40 patients [38], while it required up to 51 cases to reach an acceptable incidence of high-quality TME [41]. Therefore, it is expected that patients treated after these numbers may savor from improved surgical skills. This all underscores the importance of tertiary referral centers. As a final limitation, due to the study design, no baseline function before surgery was available.

Despite these limitations, this study provides insights into the consequences of TaTME surgery and supports the latest oncological data with acceptable LR rates after TaTME. As with every type of surgery, it is important to discuss all possible consequences (and potential treatment options) in an early phase. Embarrassment is common and patients often feel restrained in reporting functional complaints and their impact on daily life toward their surgeons. This emphasizes the importance of a postoperative care track that aims to define patient’s personalized needs and evaluates the intrinsic motivation to choose for, for example, pelvic floor rehabilitation or transanal irrigation [37]. Since data about these treatment options after TaTME are lacking, we would like to stimulate others to investigate these effects and communicate their.
In conclusion, TaTME may lead to significant functional impairments. Patients should receive preoperative counseling on this topic and be fully aware of the potential consequences of their treatment. Oncological data were in line with other short- to moderate-term data and did not show alarming results.

REFERENCES


